FDA product code · Immunology
Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions
7 FDA decisions since 1995. 2 recalls name this code, 0 of them Class I. The most-cited predicate is P950021, named by 1 later device.
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly Download the data (CSV)
Twenty years of MTG at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.
FDA decisions per year · MTG
6in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · MTG
Too few MTG 510(k)s in any year since 2007 to give a median.
Recalls per year · MTG
1in 2011
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · MTG
20in 2025
MAUDE reports naming product code MTG, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 7 | — | 0 | 0 |
| 2008 | 7 | — | 1 | 0 |
| 2009 | 3 | — | 0 | 0 |
| 2010 | 9 | — | 0 | 0 |
| 2011 | 25 | — | 1 | 3 |
| 2012 | 17 | — | 0 | 4 |
| 2013 | 12 | — | 0 | 3 |
| 2014 | 13 | — | 0 | 1 |
| 2015 | 7 | — | 0 | 9 |
| 2016 | 3 | — | 0 | 5 |
| 2017 | 9 | — | 0 | 8 |
| 2018 | 7 | — | 0 | 12 |
| 2019 | 9 | — | 0 | 13 |
| 2020 | 13 | — | 0 | 6 |
| 2021 | 7 | — | 0 | 9 |
| 2022 | 4 | — | 0 | 4 |
| 2023 | 9 | — | 0 | 5 |
| 2024 | 3 | — | 0 | 8 |
| 2025 | 6 | — | 0 | 20 |
| 2026 | 6 | — | 0 | — |
Planning a device in MTG? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.
See the 510(k) Report